Literature DB >> 6589637

A species of human alpha interferon that lacks the ability to boost human natural killer activity.

J R Ortaldo, R B Herberman, C Harvey, P Osheroff, Y C Pan, B Kelder, S Pestka.   

Abstract

Most species of recombinant leukocyte interferons (IFN-alpha A, -alpha B, -alpha C, -alpha D, -alpha F, -alpha I, and -alpha K) were capable of boosting human natural killer (NK) activity after a 2-hr treatment of cells at a concentration of 1-80 units/ml. In contrast, recombinant human IFN-alpha J was found to be incapable of augmenting NK activity after exposure of cells for 2 hr to concentrations as high as 10,000 units/ml. This inability of IFN-alpha J to boost NK activity was not complete because, after exposure of cells to a high concentration of IFN-alpha J (10,000 units/ml) for 18 hr, boosting of cytolysis was observed. IFN-alpha J appeared to interact with receptors for IFN on NK cells since it was found to interfere with the boosting of NK activity by other species of IFN-alpha. In contrast to its deficient ability to augment NK activity, IFN-alpha J has potent antiviral and antiproliferative activities. Such extensive dissociation of these biological activities has not been observed previously with any other natural or recombinant IFN species. Thus, this IFN species may be useful for evaluating the relative importance of various biological activities on the therapeutic effects of IFN, for understanding structure-function relationships, and for determining the biochemical pathways related to the various biological effects of IFN.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6589637      PMCID: PMC391605          DOI: 10.1073/pnas.81.15.4926

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  15 in total

1.  Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity.

Authors:  R R Herberman; J R Ortaldo; G D Bonnard
Journal:  Nature       Date:  1979-01-18       Impact factor: 49.962

2.  Purification and characterization of recombinant human leukocyte interferon (IFLrA) with monoclonal antibodies.

Authors:  T Staehelin; D S Hobbs; H Kung; C Y Lai; S Pestka
Journal:  J Biol Chem       Date:  1981-09-25       Impact factor: 5.157

3.  Recombinant human leukocyte interferon produced in bacteria has antiproliferative activity.

Authors:  M Evinger; S Maeda; S Pestka
Journal:  J Biol Chem       Date:  1981-03-10       Impact factor: 5.157

4.  A convenient and rapid cytopathic effect inhibition assay for interferon.

Authors:  P C Familletti; S Rubinstein; S Pestka
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

5.  Enzymology of interferon action--a short survey.

Authors:  P Lengyel
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

6.  Amino acid sequence of a human leukocyte interferon.

Authors:  W P Levy; M Rubinstein; J Shively; U Del Valle; C Y Lai; J Moschera; L Brink; L Gerber; S Stein; S Pestka
Journal:  Proc Natl Acad Sci U S A       Date:  1981-10       Impact factor: 11.205

7.  Definition and classification of the interferons.

Authors:  S Pestka; S Baron
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

8.  Purification and characterization of interferons from a continuous myeloblastic cell line.

Authors:  D S Hobbs; S Pestka
Journal:  J Biol Chem       Date:  1982-04-25       Impact factor: 5.157

9.  13 native human interferon-alpha species assessed for immunoregulatory properties.

Authors:  I Heron; M Hokland; K Berg
Journal:  J Interferon Res       Date:  1983

10.  Characteristics of human large granular lymphocytes and relationship to natural killer and K cells.

Authors:  T Timonen; J R Ortaldo; R B Herberman
Journal:  J Exp Med       Date:  1981-03-01       Impact factor: 14.307

View more
  23 in total

Review 1.  Immunological aspects of antiviral therapy.

Authors:  M Peters
Journal:  Springer Semin Immunopathol       Date:  1990

Review 2.  Interferons: current status and future directions of this prototypic biological.

Authors:  R V Smalley; E C Borden
Journal:  Springer Semin Immunopathol       Date:  1986

3.  Identification of nine interferon-alpha subtypes produced by Sendai virus-induced human peripheral blood leucocytes.

Authors:  T A Nyman; H Tölö; J Parkkinen; N Kalkkinen
Journal:  Biochem J       Date:  1998-01-15       Impact factor: 3.857

4.  Natural killer activity in patients with chronic hepatitis treated with OK432, interferon, adenine arabinoside and glycyrrhizin.

Authors:  T Wada; T Arima; H Nagashima
Journal:  Gastroenterol Jpn       Date:  1987-06

Review 5.  IFN-induced modulation of histocompatibility antigens on human cells. Background, mechanisms and perspectives.

Authors:  M Hokland; P Basse; J Justesen; P Hokland
Journal:  Cancer Metastasis Rev       Date:  1988-11       Impact factor: 9.264

6.  A panel of synthetic antibodies that selectively recognize and antagonize members of the interferon alpha family.

Authors:  S Miersch; S Kuruganti; M R Walter; S S Sidhu
Journal:  Protein Eng Des Sel       Date:  2017-09-01       Impact factor: 1.650

7.  Characterization of the murine alpha interferon gene family.

Authors:  Vincent van Pesch; Hanane Lanaya; Jean-Christophe Renauld; Thomas Michiels
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

8.  Dissecting interferon-induced transcriptional programs in human peripheral blood cells.

Authors:  Simon J Waddell; Stephen J Popper; Kathleen H Rubins; Michael J Griffiths; Patrick O Brown; Michael Levin; David A Relman
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240

9.  Impaired interferon production and natural killer cell activation in patients with the skin cancer-prone disorder, xeroderma pigmentosum.

Authors:  A A Gaspari; T A Fleisher; K H Kraemer
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

10.  Selective production of interferon-alpha subtypes by cultured peripheral blood mononuclear cells and lymphoblastoid cell lines.

Authors:  A L Greenway; M L Overall; N Sattayasai; M J Rowley; P J Hertzog; G L McMullen; B F Cheetham; S Marzuki
Journal:  Immunology       Date:  1992-01       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.